[{"arm_notes": "", "treatment_id": null, "treatment_name": "Drug : 1. Control group: Conventional treatment\n Conventional treatment: Treatments with Lopinavir / ritonavir; Hydroxychloroquine; Oxygen therapy; Non-invasive and invasive ventilaton; antibiotic therapy; renal-replacement therapy (e.g. CRRT; HD); extracorporeal membrane oxygenation (ECMO); etc. can be applied as a standard treatment for patients eligible for this study.2. Intervention group: Conventional treatment + Nafamostat IV\n Nafamostat injection- Dosage: The researcher administers a dose of 0.1 to 0.2 mg / kg / hr (2.4 to 4.8 mg / kg / day); taking into account the severity and underlying disease of the clinical trial patient.- Method of administration: Nafamostat injection is mixed with 1;000 ml of 5% DW infusion; followed by continuous infusion over 24 hours.- Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 854, "treatment_name": "Nafamostat mesilate", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]